Abcam’s Biochemicals division has entered into a license agreement with Pfizer to supply a range of authentic Pfizer compounds for use as preclinical research tools, along with Abcam Biochemicals range of more than 2000 bioactive small molecules. The agreement includes Pfizer compounds atorvastatin, doxorubicin, nifedipine and bosutinib. Abcam Biochemicals range will support preclinical research in a variety of fields such as neuroscience, cardiovascular disease, cancer and antibiotic resistance.
Steve Roome, general manager of Abcam Biochemicals, said, “We are delighted to have signed the license agreement, and to provide authentic Pfizer compounds to our customers. The compounds are an ideal complement to our current range of exceptional quality small molecules.”